Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Enrich your data and expand your research opportunities as part of a global community advancing safer and more effective therapies for better patient care.
Many clinical trials struggle to enroll patients, hindering meaningful results and delaying the delivery of therapies to patients. Real-world data (RWD) addresses this by overcoming barriers such as overly strict enrollment criteria and disconnects between research design and patients’ lived experiences.
This is a retrospective cohort analysis of approximately two million people with type 2 diabetes receiving insulin across 97 healthcare organisations using a global federated health research network (TriNetX, Cambridge, USA).
Some of the most prominent and visible roles of real-world data (RWD) and real-world evidence (RWE) are regulatory and clinical decision-making and disease research. However, RWD and RWE have been growing in influence in many other areas of healthcare and in regions all over the world.
Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.
Concerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies.
The primary aim of this study is to address the critical issue of non-standardized units in clinical laboratory data, which poses significant challenges to data interoperability and secondary usage.
Cardiovascular comorbidity increases morbidity and mortality in psoriasis. Systemic treatments, particularly biologics, are effective in alleviating skin and joint inflammation.
Good Pharmacovigilance Practices (GVP) are a set of measures put into practice in 2012 to facilitate the performance of pharmacovigilance in the European Union (EU). GVP is broken out into several modules that govern different aspects of pharmacovigilance processes.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic disease characterized by complement-mediated hemolysis, thrombophilia, bone marrow failure (BMF), and renal disease.
The University of New Mexico’s (UNM) Health Sciences Center (HSC) and Clinical & Translational Science Center (CTSC) supports high quality collaborative translational science locally, regionally, and nationally.
Upcoming Webinar
From Data to Evidence: A Framework for RWD Study Design & Causal Inference
Thursday, July 16 | 11am ET
Generating credible evidence from real-world data (RWD) requires more than access to data — it demands intentional alignment between the research question, study design, and data source. Yet even experienced teams fall into the trap of starting with the data and working backward, a shortcut that can undermine the trustworthiness of study findings.
Join TriNetX Chief Scientific Officer Jeffrey Brown, PhD, and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab at Harvard, as they walk through a practical framework for designing rigorous RWD studies for causal inference. Attendees will leave with concrete tools for sequencing their research approach, evaluating data fitness, and applying sound decision-making to their own studies.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
